Unknown

Dataset Information

0

The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries.


ABSTRACT: PURPOSE:The aim of this study is to investigate the role of health-related quality-of-life (QoL) data in relative effectiveness assessments (REAs) of new anti-cancer drugs across European jurisdictions, during health technology assessment procedures. METHODS:Comparative analysis of guidelines and publicly available REAs in six European jurisdictions of anti-cancer drugs approved by EMA between 2011 and 2013. RESULTS:Fourteen anti-cancer drugs were included, adding up to 79 REAs. Whilst all guidelines state that QoL is a relevant endpoint to determine the relative effectiveness of new cancer drugs, QoL data were included in only 54% of the 79 reports and their impact on the recommendations was limited. CONCLUSIONS:Whilst national guidelines recognize the relevance of QoL to determine the relative effectiveness of new anti-cancer drugs, this is not well-reflected in current assessments. Developing and implementing into REAs specific evidence requirements for QoL data would improve the use of this patient-centred outcome in future reimbursement and pricing decisions.

SUBMITTER: Kleijnen S 

PROVIDER: S-EPMC5548837 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries.

Kleijnen Sarah S   Leonardo Alves Teresa T   Meijboom Kim K   Lipska Iga I   De Boer Anthonius A   Leufkens Hubertus G HG   Goettsch Wim G WG  

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20170411 9


<h4>Purpose</h4>The aim of this study is to investigate the role of health-related quality-of-life (QoL) data in relative effectiveness assessments (REAs) of new anti-cancer drugs across European jurisdictions, during health technology assessment procedures.<h4>Methods</h4>Comparative analysis of guidelines and publicly available REAs in six European jurisdictions of anti-cancer drugs approved by EMA between 2011 and 2013.<h4>Results</h4>Fourteen anti-cancer drugs were included, adding up to 79  ...[more]

Similar Datasets

| S-EPMC4542123 | biostudies-literature
| S-EPMC8330755 | biostudies-literature
| S-EPMC10198844 | biostudies-literature
| S-EPMC2862718 | biostudies-literature
| S-EPMC10811184 | biostudies-literature
| S-EPMC6417405 | biostudies-literature
| S-EPMC10581102 | biostudies-literature
| S-EPMC4053440 | biostudies-literature
| S-EPMC6029637 | biostudies-other
| S-EPMC8255240 | biostudies-literature